McKesson Charges (credits) associated with last-in, first-out inventory method decreased by 106.4% to -$7.00M in Q2 2025 compared to the prior quarter. Year-over-year, this metric declined by 250.0%, from -$2.00M to -$7.00M. This is a positive signal — lower values indicate better performance for this metric.
An increase typically signals rising input costs for inventory, which may pressure future margins.
This adjustment accounts for the difference between inventory valued under the Last-In, First-Out (LIFO) method and othe...
Common among retailers using LIFO to manage tax liabilities during inflationary periods.
operating_inventory_lifo_reserve_period_charge| Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$23.00M | -$13.00M | -$13.00M | $100.00M | $2.00M | $32.00M | -$36.00M | $89.00M | -$242.00M | -$2.00M | -$16.00M | -$10.00M | $110.00M | -$7.00M |
| QoQ Change | — | +43.5% | +0.0% | +869.2% | -98.0% | >999% | -212.5% | +347.2% | -371.9% | +99.2% | -700.0% | +37.5% | >999% | -106.4% |
| YoY Change | — | — | +43.5% | +869.2% | — | +346.2% | -136.0% | >999% | — | -106.3% | +55.6% | -111.2% | +145.5% | -250.0% |
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| U.S. Pharmaceutical | $55.00M | $2.00M | -$246.00M | -$2.00M | -$2.00M | $89.00M | $0.00 | -$7.00M |
| Total | -$36.00M | $89.00M | -$242.00M | -$2.00M | -$16.00M | -$10.00M | $110.00M | -$7.00M |
U.S. Pharmaceutical was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.